Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, Lowy DR, Herrero R; Costa Rica HPV Vaccine Trial (CVT) Group.

Am J Obstet Gynecol. 2016 Aug;215(2):212.e1-212.e15. doi: 10.1016/j.ajog.2016.02.021. Epub 2016 Feb 16.

2.
3.

Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia.

Krishnappa P, Mohamad IB, Lin YJ, Barua A.

Diagn Pathol. 2014 Nov 1;9:202. doi: 10.1186/s13000-014-0202-z.

4.

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S43-9. doi: 10.1097/LGT.0b013e3182854269.

5.

Laboratory and clinical aspects of human papillomavirus testing.

Chan PK, Picconi MA, Cheung TH, Giovannelli L, Park JS.

Crit Rev Clin Lab Sci. 2012 Jul-Aug;49(4):117-36. doi: 10.3109/10408363.2012.707174. Review.

6.

The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.

Rositch AF, Silver MI, Burke A, Viscidi R, Chang K, Duke CM, Shen W, Gravitt PE.

J Low Genit Tract Dis. 2013 Jan;17(1):38-47. doi: 10.1097/LGT.0b013e3182503402.

7.

p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis.

Roelens J, Reuschenbach M, von Knebel Doeberitz M, Wentzensen N, Bergeron C, Arbyn M.

Cancer Cytopathol. 2012 Oct 25;120(5):294-307. doi: 10.1002/cncy.21205. Epub 2012 Jun 14. Review.

8.

Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.

Park Y, Lee E, Choi J, Jeong S, Kim HS.

J Clin Microbiol. 2012 Jul;50(7):2359-65. doi: 10.1128/JCM.00337-12. Epub 2012 Apr 18.

9.

Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Campos NG, Castle PE, Schiffman M, Kim JJ.

Med Decis Making. 2012 May-Jun;32(3):400-27. doi: 10.1177/0272989X11428516. Epub 2011 Dec 6.

10.

The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy.

Castle PE, Gage JC, Wheeler CM, Schiffman M.

Obstet Gynecol. 2011 Dec;118(6):1222-9. doi: 10.1097/AOG.0b013e318237caf4.

11.

Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Sahasrabuddhe VV, Luhn P, Wentzensen N.

Future Microbiol. 2011 Sep;6(9):1083-98. doi: 10.2217/fmb.11.87. Review.

12.

Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Castle PE, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Vaughan LM, Wheeler CM, Gravitt PE, Schiffman M.

J Clin Microbiol. 2011 Aug;49(8):3029-32. doi: 10.1128/JCM.00422-11. Epub 2011 Jun 1.

13.

Human papillomavirus testing in the prevention of cervical cancer.

Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE.

J Natl Cancer Inst. 2011 Mar 2;103(5):368-83. doi: 10.1093/jnci/djq562. Epub 2011 Jan 31. Review.

14.

Comparison of the DiagCor GenoFlow Human Papillomavirus Array Test and Roche Linear Array HPV Genotyping Test.

Wong FK, Ching JC, Chow JK.

Open Virol J. 2010 Nov 3;4:169-74. doi: 10.2174/1874357901004010169.

15.

Analysis of genetic copy number changes in cervical disease progression.

Policht FA, Song M, Sitailo S, O'Hare A, Ashfaq R, Muller CY, Morrison LE, King W, Sokolova IA.

BMC Cancer. 2010 Aug 16;10:432. doi: 10.1186/1471-2407-10-432.

16.

Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1675-81. doi: 10.1158/1055-9965.EPI-10-0251.

17.

Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification.

Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ.

J Clin Microbiol. 2010 Jul;48(7):2524-9. doi: 10.1128/JCM.00173-10. Epub 2010 May 12.

18.

The utility of the human papillomavirus DNA load for the diagnosis and prediction of persistent vaginal intraepithelial neoplasia.

So KA, Hong JH, Hwang JH, Song SH, Lee JK, Lee NW, Lee KW.

J Gynecol Oncol. 2009 Dec;20(4):232-7. doi: 10.3802/jgo.2009.20.4.232. Epub 2009 Dec 28.

19.

Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions.

Franco EL, Tota J.

Am J Epidemiol. 2010 Jan 15;171(2):164-8. doi: 10.1093/aje/kwp392. Epub 2009 Dec 10.

20.

Impact of improved classification on the association of human papillomavirus with cervical precancer.

Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE.

Am J Epidemiol. 2010 Jan 15;171(2):155-63. doi: 10.1093/aje/kwp390. Epub 2009 Dec 10.

Items per page

Supplemental Content

Write to the Help Desk